A new approach to protein degradation
Amphista Therapeutics is using a novel mechanism of targeted protein degradation (TPD) to hijack the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression.
Powered by transformational science, they are advancing beyond traditional degrader approaches using their proprietary Eclipsys™ Drug Development Platform. Amphista’s approach to protein degradation differentiates from traditional TPD technologies by expanding the scope for therapeutic applications and reducing the risk of resistance in oncology indications.
CEO Nicola Thompson
Advent Contact Dominic Schmidt
Advent founded and seeded Amphista in 2018.
Private Companies
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
Press Release. PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company”…
Read More
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
Press Release. Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb 4 May 2023 CAMBRIDGE, UK, May 4, 2023 - Amphista Therapeutics, a leader in next…
Read More
Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022
Press Release. Cambridge, UK – September, 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it…
Read More
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Press Release. Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39…
Read More
